A Dexcom (NSDQ:DXCM) communication on its website states that it will soon cease manufacturing for its G6 continuous glucose ...
DexCom has enormous runway for growth, not just in its home market - the U.S., but internationally as well. Manufacturing efficiencies could support their international ambitions while supporting ...
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter ...
DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback